TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01756404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
Study: NCT01405612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral administration on Day 1 or Day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Description: Intravenous infusion of 480 micrograms/kg on Days 1 to 5
Study: NCT00791908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrodessication
Description: Treatment applied to a third of the torso at each study visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Description: Laser treatment applied to a third of the torso at each study visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: potassium titanyl phosphate (KTP)
Description: Laser treatment applied to a third of the torso at each study visit.
Study: NCT02926638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Given IV
Study: NCT01060852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Detective
Description: 10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
Study: NCT00952393

Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacokinetic
Description: Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
Study: NCT01279603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GO-203-2c
Description: GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
Study: NCT01902121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin 10U + 20U
Description: Inhaled Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin 30U
Description: Inhaled Insulin
Study: NCT02451514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV vaccine
Description: Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV vaccine
Description: Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY+OMV vaccine
Description: Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and Naive Groups.
Study: NCT02536924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waiting Room Intervention
Description: The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual.
Description: The patient will receive treatment as usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual.
Description: The patient will receive treatment as usual.
Study: NCT03658044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: No intervention performed. Patients are offered to read the open pages on the website
Study: NCT04544774

Intervention type: DRUG
Intervention: AIT
Description: AIT for airborn allergens (SCIT/SLIT)

Intervention type: DIAGNOSTIC_TEST
Intervention: NAPT
Description: NAPT test with airborn allergens ( HDM, Threes, Grasses)
Study: NCT02425774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04259112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high pressure
Description: High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high pressure
Description: High-pressure pneumoperitoneum is defined as intra-abdominal pressure 12-15 mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deep neuromuscular block
Description: Deep neuromuscular block is defined as PTC 1-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deep neuromuscular block
Description: Deep neuromuscular block is defined as PTC 1-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deep neuromuscular block
Description: Deep neuromuscular block is defined as PTC 1-2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low pressure
Description: Low-pressure pneumoperitoneum is defined as intra-abdominal pressure 7-10 mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moderate neuromuscular block
Description: Moderate neuromuscular block is defined as TOF twitch 1-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moderate neuromuscular block
Description: Moderate neuromuscular block is defined as TOF twitch 1-2.
Study: NCT02550327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg
Study: NCT04916184

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: exercise training rehabilitation (aerobic exercise with/without strength training)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: exercise training rehabilitation (aerobic exercise with/without strength training)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined exercise
Description: exercise training rehabilitation (aerobic exercise with/without strength training)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined exercise
Description: exercise training rehabilitation (aerobic exercise with/without strength training)
Study: NCT02649881

Intervention type: PROCEDURE
Intervention: The heart subject will undergo OCT
Study: NCT03412916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetActive
Description: GetActive is a comprehensive, multimodal treatment that was designed to increase quality of life, resiliency and ability to cope with medical symptoms and stress. This program is rooted in the elicitation of the relaxation response, a non-judgmental state of focused attention and increased awareness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Active with Fitbit
Description: The GetActive Program for Pain with a Digital Monitoring Device (GetActive Fitbit) is identical to the GetActive with the addition of a FitBit for recording of physical activity.
Study: NCT02311465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Components of the palliative care service intervention are expected to include:~* Establishment of a palliative care plan~* Care coordination by palliative care team~* Informational, patient friendly materials supporting Palliative Care~* Communication by palliative care team to all providers and teams involved in patient's care~* Systematic collection of information, including identification of surrogate or health care proxy and advance care planning~* Questionnaires capturing health related quality of life at regular intervals throughout the intervention period
Study: NCT03696654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenotonsillar surgery
Description: when indicated, adenotonsillar surgery for SDB treatment
Study: NCT04270981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C
Description: 960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition
Study: NCT02450214

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + magnesium
Description: 50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
Study: NCT03650907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group exercise program
Description: Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Self exercise program
Description: Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
Study: NCT02619890

Intervention type: OTHER
Intervention: Brain Glioma Registry
Study: NCT01387321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Study: NCT03898765

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dry blood spot screening
Description: Dry blood spot measurement of biomarker for screening biliary atresia
Study: NCT00646412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-Part® Gel
Description: 10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
Study: NCT04256616

Intervention type: OTHER
Intervention: This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.
Description: urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC.

Intervention type: OTHER
Intervention: This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.
Description: urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced.~Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC.
Study: NCT00888303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy, total or partial
Description: Surgical standard intervention

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Thyroidectomy, total or partial
Description: Surgical standard intervention
Study: NCT04275128

Intervention type: DEVICE
Intervention: Cooled radiofrequency ablation
Description: Cooled radiofrequency thermal treatment uses the electrical current produced by radio waves to destroy a part of nerve tissue and relieve pain.
Study: NCT02425774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01801475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Pregnant \& non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Pregnant \& non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
Study: NCT00717899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry (Pony spirometer)
Description: Spirometry at rest
Study: NCT00994045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Description: Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Study: NCT03568968

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
Study: NCT01302366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBL12
Study: NCT00822185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatreptacog alfa (activated)
Description: One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
Study: NCT04275128

Intervention type: DEVICE
Intervention: Conventional radiofrequency ablation
Description: Genicular nerve ablation involves using radiofrequency to heat up the genicular nerve until it dies, causing relief of pain. This is a minimally invasive treatment that does not require any medication.
Study: NCT03711162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: GLPG1690, film-coated tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: GLPG1690, film-coated tablets for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, film-coated tablets for oral use.
Study: NCT02888847

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips Zoom! White Speed whitening lamp
Description: bleaching protocol with descending built in light intensities

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Philips Zoom! Advanced power whitening lamp
Description: bleaching protocol with high light intensity
Study: NCT02795390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02009410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon
Description: Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Creon 25000 matching Placebo
Description: Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
Study: NCT02481934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
Study: NCT04314102

Intervention type: OTHER
Intervention: No intervention will be made.
Description: No intervention will be made. Only checks will be made
Study: NCT03202862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
Study: NCT00822185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
Study: NCT03493828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block using Bupivacaine 0.5%
Description: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block using Bupivacaine 0.25%
Description: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block using Normal Saline
Description: Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.